| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biomarkers, Tumor | 13 | 2024 | 1431 | 2.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 7 | 2017 | 161 | 1.730 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 2 | 2022 | 21 | 1.530 |
Why?
|
| Melanoma | 6 | 2016 | 836 | 1.340 |
Why?
|
| Repressor Proteins | 4 | 2024 | 814 | 0.970 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2024 | 137 | 0.920 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2024 | 56 | 0.920 |
Why?
|
| Thyroid Neoplasms | 3 | 2018 | 192 | 0.900 |
Why?
|
| Brain Abscess | 1 | 2024 | 57 | 0.890 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2024 | 151 | 0.880 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2016 | 347 | 0.840 |
Why?
|
| Carcinoma, Papillary | 2 | 2013 | 76 | 0.830 |
Why?
|
| Neutropenia | 1 | 2024 | 202 | 0.830 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 44 | 0.800 |
Why?
|
| Matrix Metalloproteinase 14 | 4 | 2010 | 7 | 0.800 |
Why?
|
| Blood Platelet Disorders | 1 | 2022 | 13 | 0.800 |
Why?
|
| Mutation | 15 | 2023 | 5786 | 0.720 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 41 | 0.700 |
Why?
|
| Sarcoma, Myeloid | 1 | 2019 | 12 | 0.680 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 91 | 0.680 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 156 | 0.670 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2022 | 284 | 0.660 |
Why?
|
| Testicular Neoplasms | 1 | 2020 | 139 | 0.660 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 801 | 0.650 |
Why?
|
| Neoplasms | 5 | 2022 | 2752 | 0.630 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 412 | 0.620 |
Why?
|
| Carcinoma, Small Cell | 1 | 2018 | 50 | 0.620 |
Why?
|
| Extracellular Matrix | 2 | 2009 | 232 | 0.560 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2021 | 193 | 0.550 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 1626 | 0.550 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 532 | 0.530 |
Why?
|
| Medical Oncology | 2 | 2014 | 214 | 0.520 |
Why?
|
| ErbB Receptors | 2 | 2016 | 282 | 0.500 |
Why?
|
| cdc42 GTP-Binding Protein | 3 | 2010 | 31 | 0.500 |
Why?
|
| Molecular Targeted Therapy | 2 | 2014 | 354 | 0.490 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2016 | 80 | 0.490 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2023 | 864 | 0.460 |
Why?
|
| Genetic Techniques | 1 | 2014 | 102 | 0.450 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 431 | 0.450 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2022 | 194 | 0.440 |
Why?
|
| Humans | 49 | 2024 | 122423 | 0.430 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2014 | 121 | 0.420 |
Why?
|
| Neoplasm Invasiveness | 4 | 2013 | 608 | 0.400 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 271 | 0.380 |
Why?
|
| Immunohistochemistry | 8 | 2017 | 1714 | 0.380 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 236 | 0.370 |
Why?
|
| Carcinoma | 1 | 2013 | 282 | 0.360 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2024 | 560 | 0.360 |
Why?
|
| DNA Mutational Analysis | 4 | 2019 | 793 | 0.350 |
Why?
|
| Hepatoblastoma | 2 | 2022 | 214 | 0.330 |
Why?
|
| Genetic Testing | 2 | 2019 | 994 | 0.320 |
Why?
|
| Brain Neoplasms | 3 | 2023 | 1222 | 0.300 |
Why?
|
| Genomics | 2 | 2021 | 1474 | 0.300 |
Why?
|
| Child | 14 | 2024 | 24118 | 0.290 |
Why?
|
| Transcriptome | 1 | 2013 | 906 | 0.280 |
Why?
|
| GTP-Binding Proteins | 1 | 2006 | 175 | 0.260 |
Why?
|
| Signal Transduction | 4 | 2015 | 4513 | 0.260 |
Why?
|
| Quality Control | 2 | 2016 | 116 | 0.250 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2024 | 17 | 0.240 |
Why?
|
| Collagen | 4 | 2010 | 312 | 0.230 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2015 | 1890 | 0.230 |
Why?
|
| Adolescent | 11 | 2024 | 18984 | 0.230 |
Why?
|
| Lipids | 1 | 2006 | 504 | 0.220 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 2012 | 0.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 174 | 0.220 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 32 | 0.210 |
Why?
|
| Sequence Analysis, DNA | 4 | 2022 | 1759 | 0.210 |
Why?
|
| Female | 20 | 2024 | 64961 | 0.210 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 714 | 0.210 |
Why?
|
| Endonucleases | 2 | 2013 | 55 | 0.210 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 146 | 0.200 |
Why?
|
| Fibroma | 1 | 2022 | 30 | 0.200 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 1009 | 0.200 |
Why?
|
| Sertoli-Leydig Cell Tumor | 1 | 2022 | 16 | 0.200 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 345 | 0.200 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 70 | 0.200 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 34 | 0.200 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 41 | 0.200 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 133 | 0.190 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 1387 | 0.190 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 103 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 106 | 0.190 |
Why?
|
| Ribonuclease III | 1 | 2022 | 87 | 0.190 |
Why?
|
| Receptor, ErbB-2 | 2 | 2016 | 497 | 0.190 |
Why?
|
| Cell Movement | 3 | 2009 | 839 | 0.180 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2022 | 118 | 0.180 |
Why?
|
| Ligands | 1 | 2022 | 536 | 0.180 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 131 | 0.180 |
Why?
|
| Transcription Factors | 2 | 2022 | 2588 | 0.180 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 79 | 0.180 |
Why?
|
| Male | 17 | 2024 | 59600 | 0.170 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 61 | 0.170 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 137 | 0.170 |
Why?
|
| Sarcoma | 1 | 2022 | 197 | 0.170 |
Why?
|
| Ependymoma | 1 | 2021 | 134 | 0.170 |
Why?
|
| Cyclin B | 1 | 2019 | 23 | 0.170 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2019 | 20 | 0.170 |
Why?
|
| DNA Polymerase II | 1 | 2019 | 19 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 1119 | 0.170 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 29 | 0.170 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2019 | 13 | 0.170 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2019 | 9 | 0.170 |
Why?
|
| Infant | 4 | 2024 | 12347 | 0.160 |
Why?
|
| Azacitidine | 1 | 2019 | 55 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 1 | 2022 | 663 | 0.160 |
Why?
|
| Pyridazines | 1 | 2019 | 49 | 0.160 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 70 | 0.160 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 6 | 0.160 |
Why?
|
| Pyrazoles | 1 | 2021 | 301 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 293 | 0.160 |
Why?
|
| Hypercalcemia | 1 | 2018 | 40 | 0.160 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 33 | 0.160 |
Why?
|
| Granulosa Cell Tumor | 1 | 2018 | 40 | 0.160 |
Why?
|
| Pyrimidines | 1 | 2021 | 374 | 0.150 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 125 | 0.150 |
Why?
|
| Imidazoles | 1 | 2019 | 200 | 0.150 |
Why?
|
| Radiation Exposure | 1 | 2018 | 43 | 0.150 |
Why?
|
| Codon, Nonsense | 1 | 2018 | 131 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 178 | 0.150 |
Why?
|
| Membrane Proteins | 2 | 2024 | 1527 | 0.150 |
Why?
|
| Gene Rearrangement | 2 | 2020 | 317 | 0.150 |
Why?
|
| Stomach Neoplasms | 2 | 2013 | 538 | 0.140 |
Why?
|
| DNA Helicases | 1 | 2018 | 225 | 0.140 |
Why?
|
| Leukemia | 1 | 2020 | 375 | 0.140 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 2041 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2016 | 758 | 0.140 |
Why?
|
| Thrombocytosis | 1 | 2017 | 34 | 0.140 |
Why?
|
| Prognosis | 6 | 2019 | 4492 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 943 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 98 | 0.140 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2016 | 3 | 0.140 |
Why?
|
| Heterozygote | 1 | 2018 | 681 | 0.130 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2016 | 29 | 0.130 |
Why?
|
| Medulloblastoma | 1 | 2019 | 338 | 0.130 |
Why?
|
| Survivors | 1 | 2018 | 345 | 0.130 |
Why?
|
| Paraffin Embedding | 1 | 2016 | 31 | 0.130 |
Why?
|
| Limit of Detection | 1 | 2016 | 59 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 47 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 689 | 0.130 |
Why?
|
| Calreticulin | 1 | 2015 | 19 | 0.130 |
Why?
|
| Endothelial Cells | 2 | 2010 | 528 | 0.130 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 24 | 0.130 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2015 | 3 | 0.130 |
Why?
|
| Oxo-Acid-Lyases | 1 | 2015 | 3 | 0.130 |
Why?
|
| Ovary | 1 | 2018 | 390 | 0.130 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2015 | 16 | 0.130 |
Why?
|
| Apoptosis | 1 | 2022 | 1795 | 0.130 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2015 | 39 | 0.120 |
Why?
|
| Endometrial Neoplasms | 1 | 2016 | 99 | 0.120 |
Why?
|
| Myeloproliferative Disorders | 1 | 2015 | 90 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2017 | 221 | 0.110 |
Why?
|
| Lipoma | 1 | 2013 | 23 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 561 | 0.110 |
Why?
|
| Thymidylate Synthase | 1 | 2013 | 21 | 0.110 |
Why?
|
| DNA Primers | 1 | 2014 | 669 | 0.110 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2014 | 143 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 957 | 0.110 |
Why?
|
| Models, Biological | 2 | 2009 | 1439 | 0.110 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Aged | 7 | 2016 | 18781 | 0.100 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2012 | 12 | 0.100 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 3300 | 0.100 |
Why?
|
| Specialties, Surgical | 1 | 2013 | 79 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 803 | 0.100 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2012 | 18 | 0.100 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 1282 | 0.100 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 99 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1674 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 516 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 2794 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2012 | 110 | 0.090 |
Why?
|
| Middle Aged | 7 | 2016 | 25591 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 6303 | 0.090 |
Why?
|
| Adult | 7 | 2018 | 28746 | 0.090 |
Why?
|
| Exons | 1 | 2013 | 793 | 0.090 |
Why?
|
| Mutation, Missense | 1 | 2014 | 844 | 0.090 |
Why?
|
| Young Adult | 4 | 2022 | 8805 | 0.090 |
Why?
|
| Base Sequence | 1 | 2014 | 3119 | 0.090 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2009 | 31 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 469 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2019 | 13840 | 0.080 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2009 | 99 | 0.080 |
Why?
|
| Blood Vessels | 1 | 2009 | 102 | 0.080 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 210 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2009 | 664 | 0.080 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2006 | 5 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 312 | 0.070 |
Why?
|
| Sphingosine | 1 | 2006 | 12 | 0.070 |
Why?
|
| Receptors, Lysophosphatidic Acid | 1 | 2006 | 10 | 0.070 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2009 | 353 | 0.070 |
Why?
|
| Lysophospholipids | 1 | 2006 | 30 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 65 | 0.070 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2006 | 63 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1679 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 1076 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1234 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1874 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 77 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 100 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2009 | 927 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 398 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 871 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2022 | 66 | 0.050 |
Why?
|
| Receptor, trkB | 1 | 2021 | 20 | 0.050 |
Why?
|
| Pancreatectomy | 1 | 2022 | 135 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2022 | 92 | 0.050 |
Why?
|
| Pancreas | 1 | 2022 | 214 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2023 | 747 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1005 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 255 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 48 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2010 | 3076 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2019 | 73 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 618 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 1293 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2018 | 3 | 0.040 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2018 | 4 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 414 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2018 | 29 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2019 | 172 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 301 | 0.040 |
Why?
|
| Germ Cells | 1 | 2019 | 193 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2017 | 42 | 0.040 |
Why?
|
| Time Factors | 1 | 2006 | 6176 | 0.030 |
Why?
|
| Cerebellar Neoplasms | 1 | 2019 | 283 | 0.030 |
Why?
|
| Pathology, Surgical | 1 | 2016 | 20 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2019 | 638 | 0.030 |
Why?
|
| Pelvis | 1 | 2016 | 68 | 0.030 |
Why?
|
| Acetoacetates | 1 | 2015 | 22 | 0.030 |
Why?
|
| Polyps | 1 | 2016 | 48 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2016 | 4649 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1412 | 0.030 |
Why?
|
| Antibodies, Neoplasm | 1 | 2015 | 59 | 0.030 |
Why?
|
| Algorithms | 1 | 2022 | 1577 | 0.030 |
Why?
|
| Neoplasms, Adipose Tissue | 1 | 2013 | 8 | 0.030 |
Why?
|
| Endometrium | 1 | 2016 | 274 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 390 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1250 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 872 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 267 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 262 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4312 | 0.020 |
Why?
|
| Uterus | 1 | 2016 | 593 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 303 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 995 | 0.020 |
Why?
|
| Mice | 2 | 2022 | 17636 | 0.020 |
Why?
|
| Microscopy, Video | 1 | 2009 | 21 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 4218 | 0.020 |
Why?
|
| Integrin alpha Chains | 1 | 2009 | 16 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2009 | 35 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2013 | 524 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2009 | 30 | 0.020 |
Why?
|
| Laminin | 1 | 2009 | 59 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 55 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 2534 | 0.020 |
Why?
|
| Cues | 1 | 2009 | 88 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2009 | 33 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3073 | 0.020 |
Why?
|
| Cell Communication | 1 | 2009 | 165 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 226 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2814 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2009 | 321 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 284 | 0.020 |
Why?
|
| Antibodies | 1 | 2010 | 371 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 282 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2078 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2009 | 348 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2009 | 421 | 0.020 |
Why?
|
| Prevalence | 1 | 2013 | 2371 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 4987 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 524 | 0.020 |
Why?
|
| Animals | 2 | 2022 | 33897 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 659 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2013 | 15879 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2013 | 2998 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2012 | 5974 | 0.010 |
Why?
|